Nexvet to Host Investor Symposium at its Irish Biomanufacturing Facility

DUBLIN, Ireland, May 04, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the hosting of an Investor Symposium on June 3, 2016 at BioNua, its veterinary biologics manufacturing facility in Tullamore, Ireland. The event marks the official opening of the facility and will coincide with a Biopharma Showcase co-organised by the Irish Government agencies Enterprise Ireland and IDA Ireland, which will occur on June 2, 2016 at the National Institute for Bioprocessing Research and Training (NIBRT).

A focal point of Nexvet’s Investor Symposium at BioNua will be the emerging field of therapeutic veterinary biologics and BioNua’s growing manufacturing capabilities in this area. The Irish Biopharma Showcase is intended to provide an overview of the biopharmaceutical industry in Ireland, while facilitating connectivity between institutional investors and several of Ireland’s established and emerging biopharmaceutical companies.

"The compelling advantages of biologic therapies for chronic conditions in companion animals underpin Nexvet’s long-term vision for transforming animal medicine. Managing in-house manufacturing of our therapies in development is a key part of Nexvet’s strategy to become a vertically integrated leader in veterinary biopharmaceuticals. As we approach an operational milestone for BioNua, we are hosting this event so investors may better understand the opportunity in veterinary biopharmaceuticals, and the value we are creating through investing in manufacturing and specifically, in Ireland,” said Dr. Mark Heffernan, Chief Executive Officer of Nexvet.

BioNua is a wholly owned subsidiary comprising a 20,000 square foot facility in Tullamore, Ireland. This site was previously devoted to producing human biopharmaceuticals prior to the Company securing the facility in September, 2015. The facility historically operated under an Investigational Medicinal Products and cGMP Manufacturing licenses from Ireland's Health Products Regulatory Authority and is equipped with cGMP grade clean rooms, water for injection, purified water, and clean steam generation systems. In addition, the facility is equipped with analytical and development laboratories. Nexvet is reconfiguring the facility to be a dedicated veterinary biopharmaceutical facility using state-of-the-art disposable bioreactors, with the capability to meet the Company’s anticipated future clinical and commercial production needs for therapeutic drug substance.

To register for Nexvet’s Investor Symposium on June 3 and/or the Irish Biopharma Showcase on June 2, please RSVP by May 20, 2016 to IR@nexvet.com with your name, company and phone number. Detailed agendas will be distributed prior to both events.

About Nexvet (www.nexvet.com)

Nexvet is a veterinary biologics developer focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet’s proprietary PETization™ platform is designed to rapidly design monoclonal antibodies (mAbs) that are recognized as “self” or “native” by an animal’s immune system, a property Nexvet refers to as “100% species-specificity.” Nexvet’s product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.

Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, which conducts drug discovery in Australia, conducts clinical development in the United States and Europe and is growing its biomanufacturing capabilities in Ireland.

Further information:

Candice Knoll
Blueprint Life Science Group
+1 415-375-3340 Ext. 4

Jessica Burns
Berry & Company Public Relations
+1 212-253-8881

IDA Ireland
Jayne Wyatt
+353 1 603 4232

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements consist of all statements other than statements of historical fact, including statements regarding our future results of operations and financial position, results of any current or future pivotal safety and efficacy study, future expenditures relating to our lead product candidates, time for completion of any of our studies or facilities updates, ability to develop our pipeline of product candidates, business strategy, prospective products, ability to successfully manufacture our own product candidates, ability to meet conditions for the receipt of government grants, ability to qualify for conditional licensure or obtain product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and anticipated products. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “plan,” “potential,” “predict,” “project,” “position,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management’s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors.

Factors that could cause actual results to differ materially from our expectations expressed in this report include those summarized under Risk Factors in our reports on Forms 10-Q and 10-K and the other documents we file from time to time with the Securities and Exchange Commission. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management’s beliefs and assumptions only as of the date of this press release. Except as required by law, we do not intend, and undertake no obligation, to revise or update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Source:Nexvet Biopharma plc